Syngene International, a Biocon subsidiary, reveals an 11% revenue increase to Rs 875 crore for the first quarter. Net profit jumps 59% to Rs 87 crore. Growth is attributed to research services and biologics manufacturing. Operations commenced at Unit III in Bengaluru. Preparations advance for the Bayview facility in the US.